Patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) scores of 2 or higher compose 34% to 48% of all patients with advanced non–small cell lung cancer (NSCLC).
1,2 The ECOG PS scale indicates increasing levels of disability, with 0 indicating fully active; 1, restricted in strenuous activity; 2, restricted in work activity but ambulatory and capable of self-care; 3, capable of limited self-care; 4, completely disabled; and 5, dead. Most landmark clinical trials that led to the approval of pembrolizumab and other immune checkpoint inhibitors (ICIs) by the US Food and Drug Administration (FDA) were conducted in patients with ECOG PS scores of 0 or 1.
1,3-5 Due to better perceived tolerance of ICIs compared with cytotoxic chemotherapy, results from these clinical trials have been extrapolated to those with PS scores of 2 or higher, leading to more liberal use of pembrolizumab in this subgroup of patients, who previously might not have been considered eligible for this treatment. This is reflected in the findings from a nationwide patient-level database study that reported an overall increase in the use of systemic therapy at the end of life for patients with NSCLC, driven predominantly by ICIs (along with a concomitant decrease in use of chemotherapy) in the post–ICI approval period.
6 Moreover, treatment with ICI within 30 days prior to death was associated with decreased referral to hospice and increased in-hospital deaths.
7 While oncologists routinely use PS for decisions regarding chemotherapy,
8 rigorous evidence regarding palliative-intent ICI use according to PS is still lacking.